Bristol-Myers Squibb Company announced that it has appointed scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as senior vice president and global head of translational medicine in the company’s R&D organization, effective today.
“Enhancing our translational medicine capability is critical to achieving our mission, and we are excited to add Dr. Saha’s broad leadership experience and deep scientific expertise to our team,” said Tom Lynch, M.D., executive vice president and chief scientific officer of Bristol-Myers Squibb. “Dr. Saha will lead translational research across our therapeutic areas of focus to ensure we have the best understanding of disease and asset-specific biology so we can deliver the right drug to the right patient at the right time.”
Dr. Saha said, “Throughout my career, I have had a passion for developing translational research strategies across disease areas, including oncology and immunology. I look forward to working with Tom and the rest of the R&D organization to advance Bristol-Myers Squibb’s industry-leading pipeline in a way that pushes the boundaries of science and enables us to rapidly deliver innovative medicines to patients with even greater precision.”
Dr. Saha will initially be based at the company’s Waltham, Mass research site until its new state-of-the-art research site in Cambridge, Mass opens in the fourth quarter of 2018.
Source: Bristol-Myers Squibb
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.
Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.
Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.